Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

PURPOSE: Most lung cancers with activating epidermal growth factor receptor (EGFR) mutations respond to gefitinib, however resistance to this tyrosine kinase inhibitor (TKI) invariably ensues. The T790M mutation occurs in 50% and MET amplification in 20% of TKI-resistant tumors. Other secondary muta...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balazs, Kim, Joo H., Janne, Pasi A., Huberman, Mark S., Pao, William, Tenen, Daniel G., Kobayashi, Susumu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2596582/
https://ncbi.nlm.nih.gov/pubmed/18981003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1455
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak